Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells

• Autores principales: Henrika Jodeleit (Autor), Paula Winkelmann (Autor), Janina Caesar (Autor), Sebastian Sterz (Autor), Lesca M. Holdt (Autor), Florian Beigel (Autor), Johannes Stallhofer (Autor), Simone Breiteneicher (Autor), Eckart Bartnik (Autor), Thomas Leeuw (Autor), Matthias Siebeck (Autor), Roswitha Gropp (Autor)
• Formato: Libro
• Publicado: The Company of Biologists, 2021-01-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

This study's aim was to demonstrate that the combination of patient immune profiling and testing in a humanized mouse model of ulcerative colitis (UC) might lead to patient stratification for treatment with oxelumab. First, immunological profiles of UC patients and non-UC donors were analyzed f...